Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.05 USD
Change Today +0.06 / 3.02%
Volume 243.4K
BIOC On Other Exchanges
Symbol
Exchange
Stuttgart
As of 8:10 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

biocept inc (BIOC) Snapshot

Open
$1.95
Previous Close
$1.99
Day High
$2.07
Day Low
$1.95
52 Week High
02/25/15 - $4.91
52 Week Low
02/10/15 - $1.09
Market Cap
38.3M
Average Volume 10 Days
232.7K
EPS TTM
$-2.33
Shares Outstanding
18.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOCEPT INC (BIOC)

Related News

No related news articles were found.

biocept inc (BIOC) Related Businessweek News

No Related Businessweek News Found

biocept inc (BIOC) Details

Biocept, Inc., a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA tests utilizing a standard blood sample. The company’s tests provide information to oncologists that enable them to select the appropriate treatment for their patients based on detailed data on the characteristics of tumors. It offers OncoCEE-BR, a breast cancer CTC test that allows physician to characterize the tumor to help define treatment options; OncoCEE-LU, a test for non-small cell lung cancer; and OncoCEE-GA for gastric cancer. The company is also developing other OncoCEE CTC tests, including OncoCEE-CR for colorectal cancer; OncoCEE-PR for prostate cancer; and OncoCEE-ME for melanoma, as well as CEE-Selector, a sequencing application for various cancer types. It sells its cancer diagnostic tests directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. The company was founded in 1997 and is headquartered in San Diego, California.

42 Employees
Last Reported Date: 03/11/15
Founded in 1997

biocept inc (BIOC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $418.8K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $208.2K
Vice President of Commercial Operations
Total Annual Compensation: $177.0K
Compensation as of Fiscal Year 2014.

biocept inc (BIOC) Key Developments

Biocept and Insight Genetics to Present ALK Expression Study Data on Liquid Biopsy Platform at the IASLC World Conference on Lung Cancer

Biocept, Inc. and Insight Genetics, Inc. announced the presentation of study data at the International Association for the Study of Lung Cancer’s (IASLC) 16th Annual World Conference on Lung Cancer in Denver. “Detection of Aberrant ALK Expression from Circulating Tumor Cells for Accurate Monitoring of ALK Driven Non-Small Cell Lung Cancer” will be presented on September 7, 2015, and will describe the detection of RNA-based targets using Biocept’s proprietary liquid biopsy platform. Earlier in 2015, Biocept and Insight Genetics announced a collaboration to combine platform technologies to study RNA-based biomarker detection in circulating tumor cells (CTCs). Data demonstrate that Biocept’s proprietary CTC capture technology is compatible for detecting RNA-based targets such as ALK, which is a known driver of non-small cell lung cancer (NSCLC). Using Insight Genetics’ proprietary ALK detection assay, the two companies have been able to demonstrate the feasibility of performing RNA-based detection of ALK in both cell lines and patient samples. These studies demonstrate that Biocept’s proprietary CTC capture technology, coupled with Insight Genetics’ RNA-based biomarker detection assays, could provide a viable strategy to accurately monitor biomarker status in NSCLC patient populations. Biocept has previously demonstrated the ability to detect and quantify ALK translocations at the DNA level.

Biocept Announces Executive Changes

Biocept, Inc. announced the voluntary resignation of Bill Kachioff, Senior Vice President and Chief Financial Officer, to pursue other business opportunities. The company also announced that Mark G. Foletta has been appointed as the company’s interim Chief Financial Officer, effective immediately. Mr. Foletta served as Senior Vice President and Chief Financial Officer of Amylin Pharmaceuticals, Inc. from 2000.

Biocept, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Biocept, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of $19,245 against $76,768 a year ago. Loss from operations was $2,904,013 against $3,890,884 a year ago. Loss before income taxes was $2,996,040 against $4,034,750 a year ago. Net loss was $2,996,840 or $0.67 per basic and diluted share against $4,035,105 or $0.22 per basic and diluted share a year ago. The increase in net loss was primarily due to higher expenses associated with increased sample volume and expansion of the sales and marketing organization. For the six months, the company reported revenue of $47,520 against $226,770 a year ago. Loss from operations was $6,431,036 against $7,541,489 a year ago. Loss before income taxes was $8,123,911 against $7,834,554 a year ago. Net loss was $8,124,711 or $2.30 per basic and diluted share against $7,835,833 or $0.55 per basic and diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOC:US $2.05 USD +0.06

BIOC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Atossa Genetics Inc $0.87 USD +0.04
BioMerieux €99.17 EUR +0.87
Fluidigm Corp $10.88 USD -0.15
Illumina Inc $193.16 USD -2.29
Natera Inc $15.26 USD -0.04
View Industry Companies
 

Industry Analysis

BIOC

Industry Average

Valuation BIOC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 112.3x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 47.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOCEPT INC, please visit www.biocept.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.